GLP-1 vs GIP: The Science of Weight Loss

Modern weight loss medications target the incretin system. The two key players are GLP-1 and GIP. But what exactly do they do, and how do they differ?

GLP-1 (Glucagon-like peptide-1)

GLP-1 is a hormone produced in the gut after eating. It is the target of drugs like Wegovy (Semaglutide) and Saxenda (Liraglutide).

• Appetite: It signals the brain to reduce hunger and increase satiety (fullness).
• Digestion: It slows down gastric emptying, keeping food in the stomach longer.
• Blood Sugar: It stimulates insulin secretion when blood sugar is high.

GIP (Glucose-dependent insulinotropic polypeptide)

GIP is another incretin hormone released after eating. Historically, its role in weight loss was debated because it can promote fat storage in some contexts. However, recent research shows that when combined with GLP-1 receptor activation, GIP works synergistically to enhance metabolic benefits.

• Synergy: GIP appears to amplify the effects of GLP-1 on blood sugar and weight loss.
• Fat Metabolism: It may improve how the body processes fats and uses energy.
• Nausea Reduction: Some studies suggest GIP activation might help mitigate the nausea often caused by GLP-1 agonists.

The "Twincretin" Effect

Mounjaro (Tirzepatide) is the first medication to target both receptors simultaneously. This dual action is believed to be the reason why Tirzepatide achieves superior weight loss (up to 22.5%) compared to GLP-1 agonists alone (up to 15%).